299 related articles for article (PubMed ID: 23339304)
1. On the design of broad based screening assays to identify potential pharmacological chaperones of protein misfolding diseases.
Naik S; Zhang N; Gao P; Fisher MT
Curr Top Med Chem; 2012; 12(22):2504-22. PubMed ID: 23339304
[TBL] [Abstract][Full Text] [Related]
2. Protein Misfolding Diseases and Therapeutic Approaches.
Yadav K; Yadav A; Vashistha P; Pandey VP; Dwivedi UN
Curr Protein Pept Sci; 2019; 20(12):1226-1245. PubMed ID: 31187709
[TBL] [Abstract][Full Text] [Related]
3. Protein misfolding in disease and small molecule therapies.
Gomes CM
Curr Top Med Chem; 2012; 12(22):2460-9. PubMed ID: 23339300
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule modulation of cellular chaperones to treat protein misfolding disorders.
Sloan LA; Fillmore MC; Churcher I
Curr Opin Drug Discov Devel; 2009 Sep; 12(5):666-81. PubMed ID: 19736625
[TBL] [Abstract][Full Text] [Related]
5. Screening methods for identifying pharmacological chaperones.
Shin MH; Lim HS
Mol Biosyst; 2017 Mar; 13(4):638-647. PubMed ID: 28265599
[TBL] [Abstract][Full Text] [Related]
6. Early Stage Discovery and Validation of Pharmacological Chaperones for the Correction of Protein Misfolding Diseases.
Aubi O; Knappskog PM; Martinez A
Methods Mol Biol; 2019; 1873():279-292. PubMed ID: 30341617
[TBL] [Abstract][Full Text] [Related]
7. Repair of CFTR folding defects with correctors that function as pharmacological chaperones.
Loo TW; Clarke DM
Methods Mol Biol; 2011; 741():23-37. PubMed ID: 21594776
[TBL] [Abstract][Full Text] [Related]
8. The role of the cytosolic HSP70 chaperone system in diseases caused by misfolding and aberrant trafficking of ion channels.
Young JC
Dis Model Mech; 2014 Mar; 7(3):319-29. PubMed ID: 24609033
[TBL] [Abstract][Full Text] [Related]
9. ClpB and HtpG facilitate de novo protein folding in stressed Escherichia coli cells.
Thomas JG; Baneyx F
Mol Microbiol; 2000 Jun; 36(6):1360-70. PubMed ID: 10931286
[TBL] [Abstract][Full Text] [Related]
10. HSP70-HSP90 Chaperone Networking in Protein-Misfolding Disease.
Prodromou C; Aran-Guiu X; Oberoi J; Perna L; Chapple JP; van der Spuy J
Subcell Biochem; 2023; 101():389-425. PubMed ID: 36520314
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoperones: targeting therapeutics toward diseases caused by protein misfolding.
Ulloa-Aguirre A; Zariñán T; Conn PM
Rev Invest Clin; 2015; 67(1):15-9. PubMed ID: 25857579
[TBL] [Abstract][Full Text] [Related]
12. Role of misfolding in rare enzymatic deficits and use of pharmacological chaperones as therapeutic approach.
Pampalone G; Grottelli S; Gatticchi L; Lombardi EM; Bellezza I; Cellini B
Front Biosci (Landmark Ed); 2021 Dec; 26(12):1627-1642. PubMed ID: 34994177
[TBL] [Abstract][Full Text] [Related]
13. Therapy through chaperones: sense or antisense? Cystic fibrosis as a model disease.
Amaral MD
J Inherit Metab Dis; 2006; 29(2-3):477-87. PubMed ID: 16763920
[TBL] [Abstract][Full Text] [Related]
14. The Hsp70-Hsp90 Chaperone Cascade in Protein Folding.
Morán Luengo T; Mayer MP; Rüdiger SGD
Trends Cell Biol; 2019 Feb; 29(2):164-177. PubMed ID: 30502916
[TBL] [Abstract][Full Text] [Related]
15. Substrate Interaction Networks of the Escherichia coli Chaperones: Trigger Factor, DnaK and GroEL.
Bhandari V; Houry WA
Adv Exp Med Biol; 2015; 883():271-94. PubMed ID: 26621473
[TBL] [Abstract][Full Text] [Related]
16. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis.
Wang X; Venable J; LaPointe P; Hutt DM; Koulov AV; Coppinger J; Gurkan C; Kellner W; Matteson J; Plutner H; Riordan JR; Kelly JW; Yates JR; Balch WE
Cell; 2006 Nov; 127(4):803-15. PubMed ID: 17110338
[TBL] [Abstract][Full Text] [Related]
17. The PDB and protein homeostasis: From chaperones to degradation and disaggregase machines.
Saibil HR
J Biol Chem; 2021; 296():100744. PubMed ID: 33957121
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in understanding catalysis of protein folding by molecular chaperones.
Balchin D; Hayer-Hartl M; Hartl FU
FEBS Lett; 2020 Sep; 594(17):2770-2781. PubMed ID: 32446288
[TBL] [Abstract][Full Text] [Related]
19. Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators.
Muntau AC; Leandro J; Staudigl M; Mayer F; Gersting SW
J Inherit Metab Dis; 2014 Jul; 37(4):505-23. PubMed ID: 24687294
[TBL] [Abstract][Full Text] [Related]
20. The role of HSP70 and its co-chaperones in protein misfolding, aggregation and disease.
Duncan EJ; Cheetham ME; Chapple JP; van der Spuy J
Subcell Biochem; 2015; 78():243-73. PubMed ID: 25487025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
